October 1, 2025 Word for Word Media

Dr Lizette Louw explains how peptide receptor radionuclide therapy using Lutetium-177 radiation targets neuroendocrine tumours.

You can listen to this article below, or by using your favourite podcast player at pod.link/oncologybuddies

What are neuroendocrine tumours? Neuroendocrine tumours (NETs) are a group of rare cancers that originate in cells found throughout the body, and act as a bridge between the nervous and endocrine systems. The most common sites of origin are bowel, lung, or pancreas. Tumours are categorised as grade 1, 2 or 3 based on tumour cell growth rate, measured by the Ki-67 index on histology….

October 1, 2022 Word for Word Media
Dr Daleen Geldenhuys clarifies why neuroendocrine cancer is difficult to recognise, diagnose and treat. Neuroendocrine cells are distributed widely throughout the body. These cells serve as the communicator cells between surrounding cells and the brain. Neuroendocrine tumours can therefore arise in most organs; known by the nickname: Nearly Everywhere Tumours (NETs). While features of these tumours are unique to the site of origin, other characteristics are shared regardless of site.  The classification of NETs is independent of origin. The growth rate of the tumour and the extent of local spread determine the treatment that the patient will receive. Classification Low-grade: Growth rate…

October 1, 2022 Word for Word Media
After a year and a half of Masesi Ndaba being in and out of hospital and told there is nothing wrong with her, she was finally diagnosed with neuroendocrine cancer. She details this taxing journey. Masesi Ndaba (36) lives in Fleurhof, Gauteng with her partner and two daughters, aged 14 and six. Misdiagnosis after misdiagnosis Masesi first started experiencing chest pains in 2018. Her GP diagnosed it as acid reflux. ‘I was on medication for this for the longest time, but the chest pain only got worse,” she says. “I then got severe headaches and the doctor thought I had a skin allergy as I…